drug
paclitaxel albumin bound
Marketedupdated 5mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugpaclitaxel36 co-mentions · 27 sources
- drugSOR-00736 co-mentions · 27 sources
- tagAdCom28 co-mentions · 25 sources
- tagPMA Approval28 co-mentions · 25 sources
- company$BSXBOSTON SCIENTIFIC CORP5 co-mentions · 5 sources
- tagOncology3 co-mentions · 1 sources
- companyBaxter Healthcare Corp1 co-mentions · 1 sources
- companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 109 investigational indications.
indications
investigational
NSCLCBreast Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying paclitaxel albumin bound
- phase2Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- phase2A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
- phase2Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase2A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- phase3An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase2Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 13, 2027
130 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jul 12, 2034patentUS 9511046*PED
- Jan 12, 2034method-of-use (U-1434)US 9511046
- Sep 4, 2032patentUS 9393318*PED
- Sep 4, 2032patentUS 9597409*PED
- Mar 4, 2032method-of-use (U-1290)US 9393318
- Mar 4, 2032method-of-use (U-1290)US 9597409
- Feb 13, 2027patentUS 8034375*PED130d
- Aug 21, 2026patentUS 7758891*PED
- Aug 21, 2026patentUS 8268348*PED
- Aug 21, 2026patentUS 9101543*PED
- Aug 13, 2026method-of-use (U-1290)US 8034375
- Feb 21, 2026method-of-use (U-1434)US 7758891
- Feb 21, 2026method-of-use (U-1290)US 8268348
- Feb 21, 2026method-of-use (U-1434)US 9101543
News(10)
- Novocure hit by cyberattack exposing patient dataNovocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that unauthorized access to some of its information systems exposed patient and emp…fiercebiotech · 1mo ago
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.stat · 4mo ago
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 4mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 4mo ago
- Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 4mo ago
- Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic MelanomaMario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.onclive · 4mo ago
- Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCLLore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.onclive · 5mo ago
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 5mo ago
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 5mo ago
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that